341
A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza
Condition(s):InfluenzaLast Updated:June 28, 2022Completed
Otitis Media: 432 Clinical Trials, Page 35 of 44
Hide Studies Not Open or Pending
342
Maltese Antibiotic Stewardship Programme in the Community (MASPIC): Antibiotic Prescribing for Acute Respiratory Tract Complaints
Condition(s):Acute Respiratory InfectionLast Updated:August 8, 2018Completed
343
Safety and Efficacy of Intratympanic Application of Dexamethasone Via Catheter in Patients With Sudden Hearing Loss
Condition(s):Sudden DeafnessLast Updated:February 5, 2008Completed
344
A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus
Condition(s):Respiratory Syncytial VirusesLast Updated:December 23, 2019Terminated
345
Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age
Condition(s):InfluenzaLast Updated:September 13, 2021Completed
346
Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)
Condition(s):InfluenzaLast Updated:April 24, 2019Completed
347
A Phase III Study of an Otic Formulation in Acute Otitis Externa
Condition(s):Acute Otitis ExternaLast Updated:December 3, 2012Completed
348
Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children
Condition(s):Respiratory Syncytial Virus InfectionsLast Updated:August 28, 2013Completed
349
Caroverin and Inner Ear Diseases
Condition(s):TinnitusLast Updated:August 7, 2015Suspended
350
Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age
Condition(s):RSV InfectionLast Updated:March 23, 2023Recruiting